Janssen Biotech, Pharmacyclics Explore Abbott FISH Technology as CDx for CLL | GenomeWeb

NEW YORK (GenomeWeb News) – Abbott today announced a collaboration to explore the use of its fluorescence in situ hybridization technology as a companion diagnostic for an investigational drug being developed by Johnson & Johnson's Janssen Biotech and Pharmacyclics for treating chronic lymphocytic leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: system to track intron gains and losses, role of RUNX during mitosis, and more.

French officials release a report and move to strength safety measures for clinical trials, ScienceInsider reports.

Researchers find different molecular signatures in cancers from men as compared to those from women, the Wall Street Journal reports.

Researchers trace the deaths of a pair of newborn siblings to a mutation in their LIPT1 genes through whole-exome sequencing, Stat News reports.